FGFR1 and breast carcinoma: Notably, 1 (12.5%) of 8 breast cancer patients with FGFR1 amplification and 3 (33.3%) of 9 gastroesophageal cancer patients with FGFR2 amplification had confirmed responses with AZD4547.